Testosterone, aging and survival: Biomarker or deficiency

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 21, Issue 3, 2014, Pages 209-216

  Shores, Molly M ^a,b   Matsumoto, Alvin M ^c,d  

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^b Department of Psychiatry and Behavioral Sciences ^*  (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d Geriatric Research Education and Clinical Care (GRECC)   (United States)

Author keywords

aging; androgens; biomarker; mortality; testosterone

Indexed keywords

BIOLOGICAL MARKER; TESTOSTERONE;

ADVERSE OUTCOME; AGING; ANDROGEN DEFICIENCY; CARDIOVASCULAR DISEASE; DRUG MEGADOSE; FRAIL ELDERLY; HAZARD RATIO; HORMONAL THERAPY; HUMAN; HYPOGONADISM; MALE; MEN'S HEALTH; META ANALYSIS (TOPIC); MORTALITY; OBSERVATIONAL STUDY; REVIEW; RISK; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME; AGED; BLOOD; CARDIOVASCULAR SYSTEM; CEREBROVASCULAR ACCIDENT; CHEMICALLY INDUCED; DEFICIENCY; DRUG EFFECTS; HEART INFARCTION; MIDDLE AGED; PATHOPHYSIOLOGY; RISK FACTOR;

AGED; AGING; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK FACTORS; STROKE; TESTOSTERONE;

EID: 84899911178     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0000000000000057     Document Type: Review

References (80)

1. Handelsman DJ. Global trends in testosterone prescribing, 2000-2011: expanding the spectrum of prescription drug misuse. Med J Aust 2013; 199:548-551.
2. Rosenthal E. A push to sell testosterone gels troubles doctors. New York Times, US edition. New York: New York Times; 2013.
3. Schwartz LM, Woloshin S. Low 'T' as in 'template': how to sell disease. J Am Med Assoc Internal Med 2013; 173:1460-1462.
4. Baillargeon J, Urban RJ, Ottenbacher KJ, et al. Trends in androgen prescribing in the United States, 2001 to 2011. J Am Med Assoc Internal Med 2013; 173:1465-1466.
5. Muraleedharan V, Marsh H, Kapoor D, et al. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol 2013; 169:725-733.
6. Kyriazis J, Tzanakis I, Stylianou K, et al. Low serum testosterone, arterial stiffness and mortality in male haemodialysis patients. Nephrol Dial Transplant 2011; 26:2971-2977.
7. Schneider HJ, Wallaschofski H, Volzke H, et al. Incremental effects of endocrine and metabolic biomarkers and abdominal obesity on cardiovascular mortality prediction. PloS One 2012; 7:e33084.
8. Haring R, Nauck M, Volzke H, et al. Low serum testosterone is associated with increased mortality in men with stage 3 or greater nephropathy. Am J Nephrol 2011; 33:209-217.
9. Wehr E, Pilz S, Boehm BO, et al. Low free testosterone is associated with heart failure mortality in older men referred for coronary angiography. Eur J Heart Fail 2011; 13:482-488.
10. Hyde Z, Norman PE, Flicker L, et al. Low free testosterone predicts mortality from cardiovascular disease but not other causes: the Health in Men Study. J Clin Endocrinol Metab 2012; 97:179-189.
11. Haring R, John U, Volzke H, et al. Low testosterone concentrations in men contribute to the gender gap in cardiovascular morbidity and mortality. Gender Med 2012; 9:557-568.
12. Yeap BB, Alfonso H, Chubb SA, et al. In older men an optimal plasma testosterone is associated with reduced all-cause mortality and higher dihydrotestosterone with reduced ischemic heart disease mortality, while estradiol levels do not predict mortality. J Clin Endocrinol Metab 2014; 99:E9-18.
13. Vikan T, Schirmer H, Njolstad I, Svartberg J. Endogenous sex hormones and the prospective association with cardiovascular disease and mortality in men: the Tromso Study. Eur J Endocrinol 2009; 161:435-442.
14. Ponikowska B, Jankowska EA, Maj J, et al. Gonadal and adrenal androgen deficiencies as independent predictors of increased cardiovascular mortality in men with type II diabetes mellitus and stable coronary artery disease. Int J Cardiol 2010; 143:343-348.
15. Menke A, Guallar E, Rohrmann S, et al. Sex steroid hormone concentrations and risk of death in US men. Am J Epidemiol 2010; 171:583-592.
16. Malkin CJ, Pugh PJ, Morris PD, et al. Low serum testosterone and increased mortality in men with coronary heart disease. Heart 2010; 96:1821-1825.
17. Khaw KT, Dowsett M, Folkerd E, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 2007; 116:2694-2701.
18. Shores MM, Moceri VM, Gruenewald DA, et al. Low testosterone is associated with decreased function and increased mortality risk: a preliminary study of men in a geriatric rehabilitation unit. J Am Geriatr Soc 2004; 52:2077-2081.
19. Shores MM, Matsumoto AM, Sloan KL, Kivlahan DR. Low serum testosterone and mortality in male veterans. Arch Intern Med 2006; 166:1660-1665.
20. Tivesten A, Vandenput L, Labrie F, et al. Low serum testosterone and estradiol predict mortality in elderly men. J Clin Endocrinol Metab 2009; 94:2482-2488.
21. Lehtonen A, Huupponen R, Tuomilehto J, et al. Serum testosterone but not leptin predicts mortality in elderly men. Age Ageing 2008; 37:461-464.
22. Corona G, Monami M, Boddi V, et al. Low testosterone is associated with an increased risk of MACE lethality in subjects with erectile dysfunction. J Sex Med 2010; 7:1557-1564.
23. Militaru C, Donoiu I, Dracea O, Ionescu DD. Serum testosterone and shortterm mortality in men with acute myocardial infarction. Cardiol J 2010; 17:249-253.
24. Carrero JJ, Qureshi AR, Parini P, et al. Low serum testosterone increases mortality risk among male dialysis patients. J Am Soc Nephrol 2009; 20:613-620.
25. Phillips AC, Gale CR, Batty GD. Sex hormones and cause-specific mortality in the male veterans: the Vietnam Experience Study. QJM 2012; 105:241-246.
26. Friedrich N, Schneider HJ, Haring R, et al. Improved prediction of all-cause mortality by a combination of serum total testosterone and insulin-like growth factor I in adult men. Steroids 2012; 77:52-58.
27. Haring R, Teng Z, Xanthakis V, et al. Association of sex steroids, gonadotrophins, and their trajectories with clinical cardiovascular disease and all-cause mortality in elderly men from the Framingham Heart Study. Clin Endocrinol (Oxf) 2013; 78:629-634.
28. Gershman B, Shui IM, Stampfer M, et al. Prediagnostic circulating sex hormones are not associated with mortality for men with prostate cancer. Eur Urol 2014; 65:683-689.
29. Araujo AB, Kupelian V, Page ST, et al. Sex steroids and all-cause and causespecific mortality in men. Arch Intern Med 2007; 167:1252-1260.
30. Barrett-Connor E, Khaw KT. Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study. Circulation 1988; 78:539-545.
31. Szulc P, Claustrat B, Delmas PD. Serum concentrations of 17beta-E2 and 25-hydroxycholecalciferol (25OHD) in relation to all-cause mortality in older men: the MINOS study. Clin Endocrinol (Oxf) 2009; 71:594-602.
32. Harman SM, Metter EJ, Tobin JD, et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001; 86:724-731.
33. Araujo AB, Wittert GA. Endocrinology of the aging male. Best Pract Res Clin Endocrinol Metab 2011; 25:303-319.
34. Ng Tang Fui M, Hoermann R, Cheung AS, et al. Obesity and age as dominant correlates of low testosterone in men irrespective of diabetes status. Andrology 2013; 1:906-912.
35. Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 2002; 87:589-598.
36. Camacho EM, Huhtaniemi IT, O'Neill TW, et al. Age-associated changes in hypothalamic-pituitary-testicular function in middle-aged and older men are modified by weight change and lifestyle factors: longitudinal results from the European Male Ageing Study. Eur J Endocrinol 2013; 168:445-455.
37. Travison TG, Araujo AB, Kupelian V, et al. The relative contributions of aging, health, and lifestyle factors to serum testosterone decline in men. J Clin Endocrinol Metab 2007; 92:549-555.
38. Sartorius G, Spasevska S, Idan A, et al. Serum testosterone, dihydrotestosterone and estradiol concentrations in older men self-reporting very good health: the healthy man study. Clin Endocrinol (Oxf) 2012; 77:755-763.
39. Matsumoto AM. Testosterone administration in older men. Endocrinol Metab Clin North Am 2013; 42:271-286.
40. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010; 95:2536-2559.
41. Spratt DI, Cox P, Orav J, et al. Reproductive axis suppression in acute illness is related to disease severity. J Clin Endocrinol Metab 1993; 76:1548-1554.
42. Matsumoto AM. Andropause: clinical implications of the decline in serum testosterone levels with aging in men. J Gerontol A Biol Sci Med Sci 2002; 57:M76-99.
43. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 2005; 26:833-876.
44. Ruige JB, Mahmoud AM, De Bacquer D, Kaufman JM. Endogenous testosterone and cardiovascular disease in healthy men: a meta-analysis. Heart 2011; 97:870-875.
45. Ruige JB, Ouwens DM, Kaufman JM. Beneficial and adverse effects of testosterone on the cardiovascular system in men. J Clin Endocrinol Metab 2013; 98:4300-4310.
46. Rao PM, Kelly DM, Jones TH. Testosterone and insulin resistance in the metabolic syndrome and T2DM in men. Nature reviews. Endocrinology 2013; 9:479-493.
47. Corona G, Rastrelli G, Vignozzi L, et al. Testosterone, cardiovascular disease and the metabolic syndrome. Best Pract Res Clin Endocrinol Metab 2011; 25:337-353.
48. Oskui PM, French WJ, Herring MJ, et al. Testosterone and the cardiovascular system: a comprehensive review of the clinical literature. J Am Heart Assoc 2013; 2:e000272.
49. Herring MJ, Oskui PM, Hale SL, Kloner RA. Testosterone and the cardiovascular system: a comprehensive review of the basic science literature. J Am Heart Assoc 2013; 2:e000271.
50. Yuki A, Otsuka R, Kozakai R, et al. Relationship between low free testosterone levels and loss of muscle mass. Scientific Rep 2013; 3:1818.
51. Travison TG, Nguyen AH, Naganathan V, et al. Changes in reproductive hormone concentrations predict the prevalence and progression of the frailty syndrome in older men: the concord health and ageing in men project. J Clin Endocrinol Metab 2011; 96:2464-2474.
52. Liao CH, Lin FY, Wu YN, Chiang HS. Androgens inhibit tumor necrosis factoralpha-induced cell adhesion and promote tube formation of human coronary artery endothelial cells. Steroids 2012; 77:756-764.
53. Tsai EC, Matsumoto AM, Fujimoto WY, Boyko EJ. Association of bioavailable, free, and total testosterone with insulin resistance: influence of sex hormonebinding globulin and body fat. Diabetes Care 2004; 27:861-868.
54. Chrysohoou C, Panagiotakos D, Pitsavos C, et al. Low total testosterone levels are associated with the metabolic syndrome in elderly men: the role of body weight, lipids, insulin resistance, and inflammation; the Ikaria study. Review Diabet Stud 2013; 10:27-38.
55. Araujo AB, Dixon JM, Suarez EA, et al. Clinical review: endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2011; 96:3007-3019.
56. Haring R, Volzke H, Steveling A, et al. Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20-79. Eur Heart J 2010; 31:1494-1501.
57. Smith GD, Ben-Shlomo Y, Beswick A, et al. Cortisol, testosterone, and coronary heart disease: prospective evidence from the Caerphilly study. Circulation 2005; 112:332-340.
58. Ohlsson C, Barrett-Connor E, Bhasin S, et al. High serum testosterone is associated with reduced risk of cardiovascular events in elderly men. The MrOS (Osteoporotic Fractures in Men) study in Sweden. J Am Coll Cardiol 2011; 58:1674-1681.
59. Corona G, Monami M, Rastrelli G, et al. Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med 2011; 8:272-283.
60. Yassin A, Doros G. Testosterone therapy in hypogonadal men results in sustained and clinically meaningful weight loss. Clin Obes 2013; 3:73-83.
61. Hackett G, Cole N, Bhartia M, et al. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Int J Clin Pract 2014; 68:203-215.
62. Hackett G, Cole N, Bhartia M, et al. Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. J Sex Med 2013; 10:1612-1627.
63. Fernandez-Balsells MM, Murad MH, Lane M, et al. Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and metaanalysis. J Clin Endocrinol Metab 2010; 95:2560-2575.
64. Haddad RM, Kennedy CC, Caples SM, et al. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebocontrolled trials. Mayo Clin Proc 2007; 82:29-39.
65. Calof OM, Singh AB, Lee ML, et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 2005; 60:1451-1457.
66. Basaria S, Davda MN, Travison TG, et al. Risk factors associated with cardiovascular events during testosterone administration in older men with mobility limitation. J Gerontol A Biol Sci Med Sci 2013; 68:153-160.
67. Bhasin S, Basaria S. Diagnosis and treatment of hypogonadism in men. Best Pract Res Clin Endocrinol Metab 2010; 25:251-270.
68. Srinivas-Shankar U, Roberts SA, Connolly MJ, et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebocontrolled study. J Clin Endocrinol Metab 2010; 95:639-650.
69. Shores MM, Smith NL, Forsberg CW, et al. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab 2012; 97:2050-2058.
70. Vigen R, O'Donnell CI, Baron AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. J Am Med Assoc 2013; 310:1829-1836.
71. Finkle WD, Greenland S, Ridgeway GK, et al. Increased risk of nonfatal myocardial infarction following testosterone therapy prescription in men. PloS One 2014; 9:e85805.
72. Wu FC. Caveat emptor: does testosterone treatment reduce mortality in men? J Clin Endocrinol Metab 2012; 97:1884-1886.
73. Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med 2013; 11:108.
74. Wang F, Pan W, Wang H, et al. Relationship between thyroid function and ICU mortality: a prospective observation study. Crit Care 2012; 16:R11.
75. Rodondi N, den Elzen WP, Bauer DC, et al. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. J Am Med Assoc 2010; 304:1365-1374.
76. Nieschlag E. Klinefelter syndrome: the commonest form of hypogonadism, but often overlooked or untreated. Deutsches Arzteblatt international 2013; 110:347-353.
77. Groth KA, Skakkebaek A, Host C, et al. Clinical review: Klinefelter syndrome: a clinical update. J Clin Endocrinol Metab 2013; 98:20-30.
78. Yeap BB, Alfonso H, Chubb SA, et al. Reference ranges and determinants of testosterone, dihydrotestosterone, and estradiol levels measured using liquid chromatography-tandem mass spectrometry in a populationbased cohort of older men. J Clin Endocrinol Metab 2012; 97:4030-4039.
79. Spitzer M, Huang G, Basaria S, et al. Risks and benefits of testosterone therapy in older men. Nat Rev Endocrinol 2013; 9:414-424.
80. Gan E, Pattman S, Pearce S, Quinton R. A UK epidemic of testosterone prescribing, 2001-2010. Clin Endocrinol (Oxf) 2013; 79:564-570.